Rocket Pharmaceuticals, Inc. expected to post a loss of 42 cents a share - Earnings Preview

Rocket Pharmaceuticals

11/08/2026 12:12

Rocket Pharmaceuticals, Inc. RCKT.OQ RCKT.O is expected to  show a rise in quarterly revenue when it reports  results on November 4 (estimated) for the period ending September 30 2026
The Cranbury New Jersey-based  company is expected to report revenue of $612.36 thousand, according to the mean estimate from 11 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Rocket Pharmaceuticals, Inc. is for a loss of 42 cents per share. 
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 6 "strong buy" or "buy," 6 "hold" and 2 "sell" or "strong sell."  
The mean earnings estimate of analysts had risen by about 5.1% in the last three months. ​
Wall Street's median 12-month price target for Rocket Pharmaceuticals, Inc. is $8.50, about 133.5% above its last closing price of $3.64
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Jun. 30 2026
0.57
0.24
-0.48
Missed
-298.5
Mar. 31 2026
-0.41
-0.41
-0.42
Missed
-3.2
Dec. 31 2025
-0.48
-0.45
-0.38
Beat
16.2​
Sep. 30 2025
-0.51
-0.50
-0.45
Beat
10.9
​​Jun. 30 2025
-0.55
-0.56
-0.59
Missed
-6
Mar. 31 2025
-0.59
-0.61
-0.56
Beat
8.8​
Dec. 31 2024
-0.71
-0.72
-0.62
Beat
13.6
Sep. 30 2024
-0.75
-0.76
-0.71
Beat
6.6
This summary was machine generated August 11 at 11:12 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)